Home/Pipeline/ALN-AGT01

ALN-AGT01

Hypertension

Phase 1Active

Key Facts

Indication

Hypertension

Phase

Phase 1

Status

Active

Company

Alnylam Pharmaceuticals

About Alnylam Pharmaceuticals

Founded in 2002, Alnylam Pharmaceuticals is a leading biopharmaceutical company that pioneered the RNAi therapeutics revolution. The company leverages RNA interference technology to selectively silence genes that cause or contribute to disease, offering a fundamentally different approach to treating genetic disorders. With multiple approved therapies and a strong pipeline focused on rare diseases, Alnylam has established itself as the definitive leader in RNAi therapeutics with global reach and operations.

View full company profile

Therapeutic Areas

Rare Diseases Genetic Disorders Amyloidosis Porphyria Primary Hyperoxaluria Cardiovascular Neurology

Other Hypertension Drugs

Drug	Company	Phase	Status
Norvasc	Viatris	Approved	Commercial
Asomex	Mankind Pharma	Commercial	Active
Oxemia	Zydus Lifesciences	Approved	Commercial
Next-generation aldosterone synthase inhibitors	Mineralys Therapeutics	Preclinical	Discovery
Losartan	Granules India	Approved/Commercial	Active
Norliqva® (Amlodipine Oral Solution)	CMP Pharma	Approved	Marketed